
Overview
Background
Professor David Johnson PSM
MB BS (Hons, Univ Medal), PhD (Syd), DMed(Res), FASN, FISN, FAHMS, FRACP
Department of Kidney and Transplant Services, Division of Medicine, Building 31, Princess Alexandra Hospital
david.johnson2@health.qld.gov.au
David Johnson is full-time Director of the Metro South Kidney and Transplant Service (MSKATS) and Medical Director of the Queensland Kidney Transplant Service (QKTS) at Princess Alexandra Hospital, Professor of Medicine and Professor of Population Health at University of Queensland, and Director of the Centre for Kidney Disease Research in Brisbane, Australia. He has a number of international leadership responsibilities, including Co-Chair of the International Society of Nephrology Global Kidney Health Atlas (ISN GKHA), Co-Chair of the International Society for Peritoneal Dialysis (ISPD) Guidelines on Peritonitis Prevention and Treatment, Co-Chair of the Global PDOPPS Steering Committee, Chair of SONG-PD, Immediate Past President of the Australian and New Zealand Society of Nephrology (ANZSN), Past President of the ISPD (2018-2020), Past Councillor of the ISN (2013-2019), and member of the ISN-ACT, ISN Research and ISN Monitor groups. He is currently a chair or member of 11 national and 7 international guideline groups and is ranked by Expertscape as the “top-rated expert in dialysis in the world during the years 2013-2023.” He has influenced policy and practice through his leadership as Deputy Chair of the Australian Better Evidence And Translation in Chronic Kidney Disease (BEAT-CKD) program, Deputy Chair of the Australasian Kidney Trials Network (AKTN), Chair of the Primary Healthcare Education Advisory Committee to Kidney Health Australia (PEAK), Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party, Co-Chair of the Australasian Proteinuria Consensus Working Party, Member and Past-Chair of the ANZDATA Registry Peritoneal Dialysis Working Group, and Past-Chair of the Queensland Statewide Renal Clinical Network.
Having published over 1200 original manuscripts in peer-reviewed journals and presented over 550 abstracts at national and international scientific meetings, he brings critical expertise in designing and conducting multi-centre, multi-national randomised controlled trials (RCTs), developing national and international registries, using innovative research methodologies (such as registry-based RCTs) and implementing trial findings into practice. He has held lead roles in high-impact, large, multi-centre RCTs that have informed global clinical practice, including CKD-FIX, IDEAL, balANZ, HONEYPOT, TESTING, HERO, and IMPENDIA. He is currently principal investigator of the TEACH-PD and INCH-HD trials, and chair of the PHOSPHATE Trial Global Steering Committee. He helped establish the Australian Peritonitis Registry and led the highly successful National PD Peritonitis Quality Improvement Project, which reduced national peritonitis rates by two-thirds. He also led the universal implementation of automated laboratory reporting of eGFR in ANZ which increased national detection rates by 40%.
He has won numerous awards for both his basic science and clinical research science studies, including the ANZSN TJ Neale Award for “outstanding contributions to nephrologic science” (2005), the US National Kidney Foundation International Distinguished Medal (2014), the Canadian Society of Nephrology Dimitrios Oreopoulos Award (2017) and the Asia-Pacific Society of Nephrology Priscilla Kincaid-Smith Award (2021). He was a Queensland finalist in the Australian of the Year Awards in 2009 and was awarded a Public Service Medal by the Governor-General of Australia in 2011 for outstanding public service, particularly research into the early detection and management of kidney disease.
Availability
- Professor David Johnson is:
- Available for supervision
Fields of research
Qualifications
- Doctoral Diploma, The University of Queensland
Research interests
-
Chronic kidney disease
-
Peritoneal dialysis
-
Haemodialysis
-
Kidney transplantation
Research impacts
Chronic kidney disease (CKD) is increasingly recognised as a major public health problem in Australia and worldwide. The Centre for Kidney Disease Research (CKDR) is one of Australia’s leading kidney disease research centres with an international reputation for excellence in research. The researchers of the CKDR are working at the forefront of global trends in research to understand the cellular and molecular basis of kidney disease and to trial innovative new clinical treatments to improve the health and well-being of people with kidney disease. Renowned for its studies in acute and chronic kidney disease and kidney cancers, the CKDR has particular expertise in translating results from laboratory and clinical sciences for application to improve public health outcomes.
The vision of our research program is to increase global equity in access to affordable, sustainable, quality kidney care. Some of the major achivements of the research program to date have been determining the ideal time to commence dialysis, the role of statins in improving cardiovascular outcomes in patients with kidney disease, biocompatible peritoneal dialysis fluid use, glucose-sparing peritoneal dialysis prescriptions for people with diabetes and kidney failure, mupirocin versus honey prophylaxis in peritoneal dialysis, anaemia treatment in chronic kidney disease, the role of allopurinol in preventing CKD progression, and the role of oral steroids in IgA nephropathy. A significant dataset has also been generated from the largest health survey conducted in the world (Global Kidney Health Atlas 2017, 2019, 2023). It is available to researchers globally, has informed WHO policy, underpinned advocacy activities to put kidney health on the international agenda; allowed benchmarking of progress for individual countries; enabled longitudinal evaluation of the organisation and structure of kidney care globally to inform policy, and has been used to facilitate policy changes and care strategies in international jurisdictions (Mexico, Caribbean, Fiji, Malaysia). The program has standardised practice and halved pertioneal dialysis-related infection. Implementation of multi-pronged strategies, now emulated by Canada and USA, led to establishment of a peritonitis registry, a national quality improvement program and publication of >50 papers on peritonitis, which influenced international PD guidelines. Highly cited and adopted internationally, the International Society for Pertioneal Dialysis (ISPD Guidelines) are considered the gold standard by other kidney care guideline groups. Finally, significant knowledge has been generated through the internationally endorsed Stanardised Outcomes in NephroloGy (SONG) initiative which uses shared priorities of patients, carers and clinicians to identify core outcome measures for kidney research. The ultimate result of the research program will be patient-prioritised research questions with outputs of critical importance to the global kidney care community that will inform international guidelines and policy, build capacity for international research collaboration and leadership, facilitate kidney care quality monitoring and reporting, and improve health outcomes for people with chronic kidney disease.
Works
Search Professor David Johnson’s works on UQ eSpace
2013
Conference Publication
Introducing Nxstage haemodialysis in the Australian home
Van Eps, C., Jeffires, J., Hawley, C., Johnson, D., Campbell, S., Isbel, N. and Mudge, D. (2013). Introducing Nxstage haemodialysis in the Australian home. 49th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Brisbane Convention and Exhibition Centre, Brisbane, Australia, 9-11 September 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12121
2013
Journal Article
Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial
Petchey, William G., Hickman, Ingrid J., Prins, Johannes B., Hawley, Carmel M., Johnson, David W. and Isbel, Nicole M. (2013). Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial. Nephrology, 18 (1), 26-35. doi: 10.1111/j.1440-1797.2012.01662.x
2013
Conference Publication
A Randomised, Controlled Trial of Exit Site Application of Medihoney for the Prevention of Catheter-Associated Infections in Pd Patients - Honeypot Study
Johnson, D., Badve, S., Pascoe, E., Beller, E., Cass, A., Clark, C., De Zoysa, J., Mctaggart, S., Isbel, N. and Morrish, A. (2013). A Randomised, Controlled Trial of Exit Site Application of Medihoney for the Prevention of Catheter-Associated Infections in Pd Patients - Honeypot Study. 49th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Brisbane, QLD Australia, 9-11 September 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12121
2013
Conference Publication
Mitochondrial Homeostasis Is Impeded by Degradation and Autophagy in Oxidative Stress-Induced Renal Cell Injury
Small, David M., Bennett, Nigel C., Coombes, Jeff, Johnson, David W. and Gobe, Glenda C. (2013). Mitochondrial Homeostasis Is Impeded by Degradation and Autophagy in Oxidative Stress-Induced Renal Cell Injury. 50th European Renal Association European Dialysis and Transplant Association Congress, Istanbul Turkey, 18-21 May 2013. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ndt/gft114
2013
Conference Publication
Utility of "back up" arterio-venous fistulas in patients on peritoneal dialysis and use of central lines: A comparison between two Australian centres
Rao, N., Borlace, M., Taylor, R., Matthew, Y., Jaffrey, L., Johnson, D., Mudge, D. and Bannister, K. (2013). Utility of "back up" arterio-venous fistulas in patients on peritoneal dialysis and use of central lines: A comparison between two Australian centres. 49th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Brisbane, Australia, 9-11 September 2013. Richmond, VIC Australia: Wiley-Blackwell.
2013
Journal Article
Renal services disaster planning: lessons learnt from the 2011 Queensland floods and North Queensland cyclone experiences
Johnson, David W., Hayes, Bronwyn, Gray, Nicholas A., Hawley, Carmel, Hole, Janet and Mantha, Murty (2013). Renal services disaster planning: lessons learnt from the 2011 Queensland floods and North Queensland cyclone experiences. Nephrology, 18 (1), 41-46. doi: 10.1111/nep.12008
2013
Journal Article
Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study
Cho, Yeoungjee, Badve, Sunil V., Hawley, Carmel M., McDonald, Stephen P., Brown, Fiona G., Boudville, Neil, Wiggins, Kathryn J., Bannister, Kym M., Clayton, Philip and Johnson, David W. (2013). Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study. Peritoneal Dialysis International, 33 (1), 75-85. doi: 10.3747/pdi.2011.00317
2013
Journal Article
KHA-CARI guideline: Early chronic kidney disease: Detection, prevention and management
Johnson, D.W., Atai, E., Chan, M., Phoon, R.K.S., Scott, C., Toussaint, N.D., Turner, G.L., Usherwood, T. and Wiggins, K.J. (2013). KHA-CARI guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology, 18 (5), 340-350. doi: 10.1111/nep.12052
2013
Conference Publication
Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients
Taylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2013). Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology.
2013
Conference Publication
Short and long term biological variation of high sensitivity troponin T (HS-TnT) and N-terminal B-type natriuretic peptide (NT-PROBNP) in the stable dialysis population
Fahim, M., Hayen, A., Coburn, A., Dimeski, G., Johnson, D., Craig, J., Horvath, A. Rita, Campbell, S. and Hawley, C. (2013). Short and long term biological variation of high sensitivity troponin T (HS-TnT) and N-terminal B-type natriuretic peptide (NT-PROBNP) in the stable dialysis population. 49th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Brisbane, QLD Australia, 9-11 September 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12121
2013
Journal Article
Functional significance of erythropoietin in renal cell carcinoma
Morais, Christudas, Johnson, David W., Vesey, David A. and Gobe, Glenda C. (2013). Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer, 13 (1) 14, 14.1-14.7. doi: 10.1186/1471-2407-13-14
2013
Conference Publication
Competitive risks of encapsulating peritoneal sclerosis and death in pertioneal dialysis
Lambie, Mark, Bankart, John, Johnson, David, Mactier, Robert, Phillips-Darby, Louise, Topley, Nick and Davies, Simon (2013). Competitive risks of encapsulating peritoneal sclerosis and death in pertioneal dialysis. 50th European Renal Association - European Dialysis and Transplant Association Congress, Istanbul, Turkey, 18-21 May 2013 . Oxford, United Kingdom : Oxford University Press.
2012
Journal Article
Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis
Rossi, Megan, Klein, Kerenaftali, Johnson, David W. and Campbell, Katrina L. (2012). Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. International Journal of Nephrology, 2012 673631, 673631.1-673631.20. doi: 10.1155/2012/673631
2012
Journal Article
Clinician beliefs and attitudes about home haemodialysis: a multinational interview study
Tong, Allison, Palmer, Suetonia, Manns, Braden, Craig, Jonathan C., Ruospo, Marinella, Gargano, Letizia, Johnson, David W., Hegbrant, Jorgen, Olsson, Mans, Fishbane, Steven and Strippoli, Giovanni F. M. (2012). Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. BMJ Open, 2 (6) e002146, e002146.1-e002146 .12. doi: 10.1136/bmjopen-2012-002146
2012
Journal Article
End-stage kidney disease due to haemolytic uraemic syndrome – outcomes in 241 consecutive ANZDATA registry cases
Tang, Wen, Mohandas, Janaki, McDonald, Stephen P., Hawley, Carmel M., Badve, Sunil V., Boudville, Neil, Brown, Fiona G., Clayton, Philip A., Wiggins, Kathryn J., Bannister, Kym M., Campbell, Scott B. and Johnson, David W. (2012). End-stage kidney disease due to haemolytic uraemic syndrome – outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrology, 13 (1) 164, 164.1-164.11. doi: 10.1186/1471-2369-13-164
2012
Journal Article
The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial
Johnson, David W., Brown, Fiona G., Clarke, Margaret, Boudville, Neil, Elias, Tony J., Foo, Marjorie W. Y., Jones, Bernard, Kulkarni, Hemant, Langham, Robyn, Ranganathan, Dwarakanathan, Schollum, John, Suranyi, Michael G., Tan, Seng H. and Voss, David (2012). The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation, 27 (12), 4445-4453. doi: 10.1093/ndt/gfs314
2012
Journal Article
Frank-ter Haar syndrome associated with sagittal craniosynostosis and raised intracranial pressure
Bendon, Charlotte L., Fenwick, Aimee L., Hurst, Jane A., Nuernberg, Gudrun, Nuernberg, Peter, Wall, Steven A., Wilkie, Andrew O. M. and Johnson, David (2012). Frank-ter Haar syndrome associated with sagittal craniosynostosis and raised intracranial pressure. Bmc Medical Genetics, 13 104. doi: 10.1186/1471-2350-13-104
2012
Journal Article
NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation
Barraclough, Katherine A., Isbel, Nicole M., Lee, Katie J., Bergmann, Troels K., Johnson, David W., McWhinney, Brett C., Ungerer, Jacobus P. J., Campbell, Scott B., Leary, Diana R., Bialasiewicz, Seweryn, Rockett, Rebecca J. and Staatz, Christine E. (2012). NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation, 94 (10), 1025-1032. doi: 10.1097/TP.0b013e31826c3985
2012
Journal Article
A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial
Barraclough, Katherine A., Brown, Fiona, Hawley, Carmel M., Leary, Diana, Noble, Euan, Campbell, Scott B., Isbel, Nicole M., Mudge, David W., van Eps, Carolyn L. and Johnson, David W. (2012). A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrology, Dialysis, Transplantation, 27 (11), 4146-4153. doi: 10.1093/ndt/gfs372
2012
Journal Article
A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients -- the HEALTHY-CATH trial
Broom, Jennifer K., Krishnasamy, Rathika, Hawley, Carmel M., Playford, Elliot G. and Johnson, David W. (2012). A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients -- the HEALTHY-CATH trial. BMC Nephrology, 13 (1 Article No.146) 146, 146. doi: 10.1186/1471-2369-13-146
Funding
Current funding
Past funding
Supervision
Availability
- Professor David Johnson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Improving outcomes for people treated with peritoneal dialysis
Principal Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Novel Approaches to Cardiovascular Risk Stratification in Chronic Kidney Disease
Principal Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Evaluating the risk factors of poor health and equity of healthcare access in children living with chronic kidney disease
Principal Advisor
-
-
Doctor Philosophy
Viral Complications Following Kidney Transplantationn
Associate Advisor
Other advisors: Associate Professor Nikky Isbel, Professor Carmel Hawley, Associate Professor Andrea Viecelli
-
Doctor Philosophy
Patient-centred strategies to improve life goal attainment in people with kidney disease
Associate Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Predictors of and interventions to improve uptake and technique survival and reduce burden of home dialysis treatment
Associate Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Perioperative outcomes and risk assessment of patients on chronic kidney replacement therapy
Associate Advisor
Other advisors: Professor Carmel Hawley
-
Doctor Philosophy
Increemental dialysis to improve health outcomes in people starting haemodialysis
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Andrea Viecelli
-
Master Philosophy
Standardised Reporting of Cardiovascular Outcomes in Kidney Transplant Recipients
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Andrea Viecelli
Completed supervision
-
2025
Doctor Philosophy
Epidemiology, Treatment and Outcomes of Focal Segmental Glomerulosclerosis and Membranous Nephropathy
Principal Advisor
-
2022
Doctor Philosophy
Strategies to improve infectious complications in kidney transplant patients
Principal Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Ross Francis
-
2016
Doctor Philosophy
Therapeutic interventions to improve clinical outcomes in advanced chronic kidney disease
Principal Advisor
Other advisors: Professor Carmel Hawley
-
2015
Doctor Philosophy
Inflammation in Peritoneal Dialysis: Investigating the Roles of Biocompatible Solutions and Biological Markers
Principal Advisor
Other advisors: Professor Carmel Hawley, Professor David Mudge
-
2005
Doctor Philosophy
IGF FAMILY MEMBERS IN RENAL CELL CARCINOMA: THEIR ROLES IN MALIGNANCIES AND THERAPEUTIC INTERVENTIONS
Principal Advisor
-
2019
Doctor Philosophy
Strategies to Improve Vascular Access Outcomes in Haemodialysis Patients
Joint Principal Advisor
Other advisors: Professor Carmel Hawley
-
2025
Doctor Philosophy
Establishing the Role of Metformin for ADPKD Through Therapeutic Investigation and Guideline Development
Associate Advisor
Other advisors: Dr Christine Staatz, Professor Carmel Hawley, Associate Professor Andrea Viecelli, Dr Andrew Mallett
-
2024
Doctor Philosophy
Improving Kidney Disease Detection and Risk Prediction Across Diverse Regional and Socioeconomic Settings
Associate Advisor
Other advisors: Associate Professor Sally Shrapnel
-
2022
Doctor Philosophy
Nutrition supplementation and gut health in chronic kidney disease
Associate Advisor
Other advisors: Dr Katrina Campbell
-
2020
Doctor Philosophy
The role of the adipose tissue microenvironment in kidney cancer
Associate Advisor
Other advisors: Associate Professor David Vesey, Dr Sumaira Hasnain
-
2019
Master Philosophy
Very early acute rejection in an Australian and New Zealand kidney transplant population
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Yeoung Jee Cho, Associate Professor Ross Francis, Professor David Mudge
-
2016
Doctor Philosophy
Cardiac Biomarkers for The Diagnosis and Monitoring of Cardiovascular Disease in The Dialysis Population
Associate Advisor
Other advisors: Professor Carmel Hawley
-
2015
Doctor Philosophy
IDENTIFICATION OF POTENTIAL MEDIATORS OF OXIDATIVE DAMAGE AND TARGETS FOR NOVEL TREATMENTS FOR CHRONIC KIDNEY DISEASE
Associate Advisor
Other advisors: Professor Jeff Coombes
-
2015
Doctor Philosophy
Uraemic toxins & Synbiotics: A novel therapy for Chronic Kidney Disease
Associate Advisor
Other advisors: Dr Katrina Campbell
-
2013
Doctor Philosophy
Mechanisms of Cytoprotection by Erythropoietin (EPO) in the Hypoxia/Ischaemia-Injured Neonatal Brain
Associate Advisor
-
2010
Doctor Philosophy
Androgen receptor, caveolin-1 and androgen self-sufficiency in prostate cancer
Associate Advisor
Other advisors: Honorary Professor John Hooper
-
2009
Doctor Philosophy
Targeting genes for identification and treatment of renal cell carcinoma
Associate Advisor
Other advisors: Associate Professor David Vesey
-
2008
Doctor Philosophy
Targeting the myofibroblast to limit renal fibrosis: a model using cancer therapies
Associate Advisor
-
2004
Doctor Philosophy
MOLECULAR MECHANISM FOR RENAL FIBROSIS: ROLE OF THE MAPK FAMILY
Associate Advisor
-
Doctor Philosophy
Genetic Diagnostics in Genetic Renal Disease: Methods, Applications and Therapeutics
Associate Advisor
Media
Enquiries
For media enquiries about Professor David Johnson's areas of expertise, story ideas and help finding experts, contact our Media team: